Cargando…
Monoclonal Antibodies against Calcitonin Gene-Related Peptide for Migraine Prophylaxis: A Systematic Review of Real-World Data
Objective: To perform a systematic review of real-world outcomes for anti-CGRP-mAbs. Methods: Following the PRISMA guidelines, we searched PubMed for real-world data of erenumab, galcanezumab, fremanezumab, or eptinezumab in patients with migraines. Results: We identified 134 publications (89 retros...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9819019/ https://www.ncbi.nlm.nih.gov/pubmed/36611935 http://dx.doi.org/10.3390/cells12010143 |
_version_ | 1784865128118747136 |
---|---|
author | Pavelic, Antun R. Wöber, Christian Riederer, Franz Zebenholzer, Karin |
author_facet | Pavelic, Antun R. Wöber, Christian Riederer, Franz Zebenholzer, Karin |
author_sort | Pavelic, Antun R. |
collection | PubMed |
description | Objective: To perform a systematic review of real-world outcomes for anti-CGRP-mAbs. Methods: Following the PRISMA guidelines, we searched PubMed for real-world data of erenumab, galcanezumab, fremanezumab, or eptinezumab in patients with migraines. Results: We identified 134 publications (89 retrospective), comprising 10 pharmaco-epidemiologic and 83 clinic-based studies, 38 case reports, and 3 other articles. None of the clinic-based studies provided follow-up data over more than one year in more than 200 patients. Findings suggest that there are reductions in health insurance claims and days with sick-leave as well as better treatment adherence with anti-CGRP-mAbs. Effectiveness, reported in 77 clinic-based studies, was comparable to randomized controlled trials. A treatment pause was associated with an increase in migraine frequency, and switching to another antibody resulted in a better response in some of the patients. Adverse events and safety issues were addressed in 86 papers, including 24 single case reports. Conclusion: Real-world data on anti-CGRP-mAbs are limited by retrospective data collection, small patient numbers, and short follow-up periods. The majority of papers seem to support good effectiveness and tolerability of anti-CGRP-mAbs in the real-world setting. There is an unmet need for large prospective real-world studies providing long-term follow-ups of patients treated with anti-CGRP-mAbs. |
format | Online Article Text |
id | pubmed-9819019 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-98190192023-01-07 Monoclonal Antibodies against Calcitonin Gene-Related Peptide for Migraine Prophylaxis: A Systematic Review of Real-World Data Pavelic, Antun R. Wöber, Christian Riederer, Franz Zebenholzer, Karin Cells Review Objective: To perform a systematic review of real-world outcomes for anti-CGRP-mAbs. Methods: Following the PRISMA guidelines, we searched PubMed for real-world data of erenumab, galcanezumab, fremanezumab, or eptinezumab in patients with migraines. Results: We identified 134 publications (89 retrospective), comprising 10 pharmaco-epidemiologic and 83 clinic-based studies, 38 case reports, and 3 other articles. None of the clinic-based studies provided follow-up data over more than one year in more than 200 patients. Findings suggest that there are reductions in health insurance claims and days with sick-leave as well as better treatment adherence with anti-CGRP-mAbs. Effectiveness, reported in 77 clinic-based studies, was comparable to randomized controlled trials. A treatment pause was associated with an increase in migraine frequency, and switching to another antibody resulted in a better response in some of the patients. Adverse events and safety issues were addressed in 86 papers, including 24 single case reports. Conclusion: Real-world data on anti-CGRP-mAbs are limited by retrospective data collection, small patient numbers, and short follow-up periods. The majority of papers seem to support good effectiveness and tolerability of anti-CGRP-mAbs in the real-world setting. There is an unmet need for large prospective real-world studies providing long-term follow-ups of patients treated with anti-CGRP-mAbs. MDPI 2022-12-29 /pmc/articles/PMC9819019/ /pubmed/36611935 http://dx.doi.org/10.3390/cells12010143 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Pavelic, Antun R. Wöber, Christian Riederer, Franz Zebenholzer, Karin Monoclonal Antibodies against Calcitonin Gene-Related Peptide for Migraine Prophylaxis: A Systematic Review of Real-World Data |
title | Monoclonal Antibodies against Calcitonin Gene-Related Peptide for Migraine Prophylaxis: A Systematic Review of Real-World Data |
title_full | Monoclonal Antibodies against Calcitonin Gene-Related Peptide for Migraine Prophylaxis: A Systematic Review of Real-World Data |
title_fullStr | Monoclonal Antibodies against Calcitonin Gene-Related Peptide for Migraine Prophylaxis: A Systematic Review of Real-World Data |
title_full_unstemmed | Monoclonal Antibodies against Calcitonin Gene-Related Peptide for Migraine Prophylaxis: A Systematic Review of Real-World Data |
title_short | Monoclonal Antibodies against Calcitonin Gene-Related Peptide for Migraine Prophylaxis: A Systematic Review of Real-World Data |
title_sort | monoclonal antibodies against calcitonin gene-related peptide for migraine prophylaxis: a systematic review of real-world data |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9819019/ https://www.ncbi.nlm.nih.gov/pubmed/36611935 http://dx.doi.org/10.3390/cells12010143 |
work_keys_str_mv | AT pavelicantunr monoclonalantibodiesagainstcalcitoningenerelatedpeptideformigraineprophylaxisasystematicreviewofrealworlddata AT woberchristian monoclonalantibodiesagainstcalcitoningenerelatedpeptideformigraineprophylaxisasystematicreviewofrealworlddata AT riedererfranz monoclonalantibodiesagainstcalcitoningenerelatedpeptideformigraineprophylaxisasystematicreviewofrealworlddata AT zebenholzerkarin monoclonalantibodiesagainstcalcitoningenerelatedpeptideformigraineprophylaxisasystematicreviewofrealworlddata |